A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 493-505

  Janni, Wolfgang ^a   Sarosiek, Tomasz ^b   Karaszewska, Boguslawa ^c   Pikiel, Joanna ^d   Staroslawska, Elzbieta ^e   Potemski, Piotr ^f   Salat, Christoph ^c   Brain, Etienne ^g   Caglevic, Christian ^h   Briggs, Kathryn ⁱ   Desilvio, Michelle ^j   Marini, Luca ⁱ   Papadimitriou, Christos ^k  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NZOZ Centrum Medyczne   (Poland)

^c Przychodnia Lekarska NZOZ KOMED ^*  (Germany)

^d Poradnia Onkologiczna   (Poland)

^e Centrum Onkologii Ziemi Lubelskej   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g INSTITUT CURIE   (France)

^h Instituto Oncológico Fundación Arturo López Pérez   (Chile)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j GLAXOSMITHKLINE   (United States)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

Breast cancer; Capecitabine; HER2; Lapatinib; Vinorelbine

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, ERBB-2; VINBLASTINE;

EID: 84894047241     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2828-z     Document Type: Article

References (32)

1. Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26:51-59
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
3. Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245-R262
4. Swain SM, Kim SB, Cortes J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471
5. Blackwell KL, Burstein HJ, Sledge G, Stein S, Ellis C, Casey M, Baselga J, O'Shaughnessy J (2009) Updated survival analysis of a randomized study of lapatinib alone or in combination with tastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 69:3
6. Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130
7. Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30:2585-2592
8. Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543
9. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730
10. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Caraceni A, Martini C, Bonadonna G (1996) Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 39:285-291
11. Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252
12. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM (2012) Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol 23:1023-1029
13. Brain E, Isambert N, Dalenc F et al (2012) Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer 106:673-677
14. Saip P, Erlap Y, Ozkan M, Karaca H, Benekli M, Cetin B, Isikdogan A, Kucukoner M, Basaran G (2011) Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer. J Clin Oncol 29 (suppl; abstr e13079)
15. Chew HK, Schwartzberg LS, Bandarinath S, Rubin P, Schumaker G, Daugherty JP, DeSilvio M, Mahoney JM (2013) Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer. Presented at the American Society of Clinical Oncology Symposium 2013; May 30-June 3 2013; Chicago, Illinois (Abstract 621)
16. Janni W, Sarosiek T, Papadimitriou C, Álvarez Gallego J, Caruso M, Wiest W, Lim M, Andersson H, Das-Gupta A (2011) A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): safety results. J Clin Oncol 29 (suppl; abstr e11097)
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
18. Berry G, Kitchin RM, Mock PA (1991) A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 10:749-755
19. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743
20. Xu BH, Jiang ZF, Chua D et al (2011) Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 30:327-335
21. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924-934
22. FDA (2011) FDA Approval for Lapatinib Ditosylate. http://www.cancer.gov/ cancertopics/druginfo/fda-lapatinib/. Acessed April 2013
23. Yip AY, Tse LA, Ong EY, Chow LW (2010) Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 21:487-493
24. + metastatic breast cancer: interim analysis (IA) of NCIC CTG. MA.31/GSK EGF 108919. J Clin Oncol 30 (suppl; abstr LBA671)
25. Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640
26. Guarneri V, Frassoldati A, Bottini A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989-1995
27. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar C, Norman Atkins J, Fehrenbacher L, Douglas Bear H, Baez-Diaz L (2012) Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 30 (suppl; abstr LBA506)
28. Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119
29. Extra JM, Antoine EC, Vincent-Salomon A et al (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15:799-809
30. von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27:1999-2006
31. Petrelli F, Barni S (2013) A pooled analysis of 2,618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer 13:81-87
32. Verma S, Miles D, Gianni L et al (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 367:1783-1791